Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
REGULATORY
MHLW to Set Criteria for Exemptions under OTC-Like Drug Charge Scheme
The Ministry of Health, Labor and Welfare (MHLW) plans to establish criteria for patients who would be exempt from additional charges under the proposed system for “OTC-like” prescription drugs, a senior MHLW official said on April 15. Speaking at a…
To read the full story
Related Article
- MHLW Panel Finalizes Exemptions for OTC-Like Drug Charges
August 17, 2026
- MHLW to Hear Patient Groups on OTC-Like Drug Charge Exemptions
July 27, 2026
- MHLW Eyes Limited Charge Exemptions for OTC-Like Topical Drugs
July 24, 2026
- MHLW Panel Examines Indication Mapping for OTC-Like Drug Charge Scheme
July 13, 2026
- MHLW Starts Technical Review of OTC-Like Drug Charge Exemptions
June 29, 2026
- MHLW Panel OKs Technical Review Group for OTC-Like Drug Charge System
June 19, 2026
- Japan Enacts Reform Bill Paving Way for OTC-Like Drug Charges
June 1, 2026
- Japan Minister Rules Out Full Self-Pay for OTC-Like Drugs
April 30, 2026
- Health Insurance Reform Bill Sails Through Lower House
April 30, 2026
- Health Insurance Reform Bill Clears Lower House Committee, Draws Backlash
April 27, 2026
- MHLW to Exclude High School-Age and Younger from OTC-Like Drug Charge: Official
April 23, 2026
- Extra Charges Likely for OTC-Like Drugs to Treat Seasonal Conditions: Minister
April 22, 2026
- Health Insurance Reform Bill Enters Diet Debate; OTC-Like Drug Charges in Focus
April 10, 2026
- MHLW Panel Calls for Careful Design of OTC-Like Drug Charge System
March 23, 2026
- Cabinet-Backed Health Insurance Bill Targets Childbirth Costs, Copay Reform
March 16, 2026
- Japan Cabinet Approves Health Insurance Bill with OTC-Like Drug Charges
March 16, 2026
REGULATORY
- PMDA Generic GMP Inspections a Real-World Test to Stem Startup Risks: Official
September 8, 2026
- CEA Review Finds Past Decisions Sound, Sees Room for More Transparency
September 8, 2026
- MHLW Adds Pomalyst Generics to RevMate Safety Program
September 8, 2026
- Japan Extends Shelf Life of Stockpiled Xofluza to 9 Years
September 8, 2026
- MHLW Seeks at Least 275 Billion Yen to Shore Up Drug Supplies
September 7, 2026
Japanese Prime Minister Sanae Takaichi has pledged to respond to the US most-favored-nation (MFN) drug pricing policy to safeguard timely…
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…